Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...
A study published in Molecular Psychiatry reveals a path of cause-effect molecular events that can lead to Alzheimer’s disease (AD). Researchers at Baylor College of Medicine, Duncan Neurological ...
The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025. The US Food and Drug Administration (FDA) has granted Fast ...
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
Copyright: © 2025 The Author(s). Published by Elsevier Ltd. C3 glomerulopathy is an ultra-rare, severe form of glomerulonephritis caused by overactivation of the ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial. The US Food and Drug Administration (FDA) has approved the Investigational New Drug ...
Forbes contributors publish independent expert analyses and insights. Scott Hutcheson teaches leadership at Purdue University. In biology, nothing changes all at once. A single cell fires, a chemical ...
Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but Apellis Pharmaceuticals has delivered a checkmate with a wider label and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results